MicroRNA‑24‑3p inhibition prevents cell growth of vascular smooth muscle cells by targeting Bcl‑2‑like protein 11

Abstract

Numerous reports have shown that dysfunction of vascular smooth muscle cells (VSMCs) serves a critical function in the development of cardiovascular disease, including coronary heart disease (CHD). microRNAs (miRNAs/miRs) have been reported to play important roles in regulating the function of VSMCs. The present study aimed to determine the role of miR-24-3p in VSMCs and to uncover the underlying mechanism. The expression of miR-24-3p in the peripheral blood samples of CHD patients was measured by reverse transcription-quantitative (RT-q) PCR. It was found that the level of miR-24-3p in the peripheral blood of patients with CHD was significantly upregulated compared with that in healthy controls. A dual luciferase reporter assay was performed to determine whether Bcl-2-like protein 11 (Bcl-2L11) was a target gene of miR-24-3p, and it was identified that Bcl-2L11 was a direct target of miR-24-3p. The mRNA level and protein expression of Bcl-2L11 in the peripheral blood of patients with CHD were measured by RT-qPCR and western blotting, respectively. The findings suggested that Bcl-2L11 was downregulated in the peripheral blood of patients with CHD. In addition, it was found that downregulation of miR-24-3p suppressed VSMC proliferation and promoted VSMC apoptosis, while the effects of the miR-24-3p inhibitor on cell viability and apoptosis were reversed by Bcl-2L11-small interfering (si)RNA. Additionally, downregulation of miR-24-3p increased the levels of Bcl-2L11, caspase-3 and Bax, and decreased Bcl-2 expression in VSMCs; these changes were abolished by Bcl-2L11-siRNA. In conclusion, the aforementioned results indicated that miR-24-3p was an important regulator in VSMC proliferation and apoptosis by targeting Bcl-2L11, which suggested that miR-24-3p might be a potential therapeutic target for the treatment of CHD.

Long noncoding RNA PVT1 accelerates the growth of placental trophoblasts in preeclampsia through the microRNA‐24‐3p/HSD11B2 axis

“…miR‐24‐3p is an important member of the miRNA family and is widely expressed in various tissues of mammals. For example, the blood lipid of miR‐24‐3p in the peripheral blood of patients with coronary heart disease was upregulated (Zhang et al, 2020). Also, increased miR‐24‐3p was observed in degenerative nucleus pulposus cells (Z. Chen et al, 2020).…”

circBTBD7 Promotes Immature Porcine Sertoli Cell Growth through Modulating miR-24-3p/MAPK7 Axis to Inactivate p38 MAPK Signaling Pathway

“…These abovementioned clues indicate that circBTBD7 acted as a sponge of miR-24-3p to participate in regulating immature porcine Sertoli cell growth. miR-24-3p, highly conserved in animal species, has been witnessed to control the cell proliferation in multiple cell types, including skeletal muscle-derived progenitor cells [29], vascular smooth muscle cells [30], colon cancer cells [31], and human arterial smooth muscle cells [32]. RNA-seq data investigation shows that miR-24-3p exhibits a developmentalstage-specific expression profile in porcine testicular tissues [33,34].…”

Role of miR‐15a‐5p and miR‐199a‐3p in the inflammatory pathway regulated by NF‐κB in experimental and human atherosclerosis

“…However, it has been described that the alteration in the expression profile of miRNAs might be related to human diseases, such as atherosclerosis. For instance, miR‐145 and miR‐143 regulate vascular smooth muscle cells (VSMCs) fate and plasticity, 13 whereas miR‐24‐3p has been described as an important regulator in VSMCs proliferation and apoptosis 14 …”

“…For instance, miR-145 and miR-143 regulate vascular smooth muscle cells (VSMCs) fate and plasticity, 13 whereas miR-24-3p has been described as an important regulator in VSMCs proliferation and apoptosis. 14 Atherosclerosis is an asymptomatic disease for long periods in which several factors can contribute to the progression and rupture of vulnerable plaques and, consequently, provoke the acute event such as stroke or acute myocardial infarction. 15 In this regard, to identify new biomarkers, miRNAs or miRNA panels will help in the future to detect the presence of vulnerable plaques, but also to avoid the progression process.…”